Glenmark Pharmaceuticals receives EIR from US FDA for its Monroe facility
Glenmark Pharmaceuticals, a research-led, global pharmaceutical company announced that it has received the Establishment…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Glenmark Specialty secures NMPA approval for RYALTRIS nasal spray
Commercialisation to be undertaken by Grand Pharmaceuticals under existing exclusive licensing agreement
Glenmark to launch Ropivacaine Hydrochloride Injection USP in the US
Marc Kikuchi, President & Business Head, North America, highlights the new addition to Glenmark’s injectable portfolio and…
Glenmark Pharmaceuticals to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) single-dose…
Glenmark Pharmaceuticals, a research‐led, global pharmaceutical company has announced the launch of Eribulin Mesylate Injection, 1…
Glenmark to launch generic version of Adderall Tablets in the US market by May 2025
Company announces bioequivalent and therapeutically equivalent version of Mixed Salts of a Single Entity Amphetamine Product…
Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for injection in the US
The company introduces Vancomycin Hydrochloride for Injection USP in three dosage strengths, expanding its injectable product…
Glenmark USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose…
Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA
Glenmark announces launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial
The launch is eligible for 180 days of CGT exclusivity under the FD&C Act
Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution in the US
Latanoprost Ophthalmic Solution, 0.005 per cent introduced as a bioequivalent alternative to Xalatan
Glenmark launches Clindamycin Phosphate Foam
The new product targets a market worth $5.8 million